Alan Green & Sarah Lowther discuss the market crash, lessons from China, plus an array of stocks including Tiziana Life #TILS & Open Orphan #ORPH on the Total Market Solutions podcast March 15, 2020 – Posted in: Open Orphan (ORPH), Tiziana Life Sciences (TILS)

Friday The 13th & The Weekend Podcast Alan Green Joins Sarah Lowther To Talk All Things Markets During this weekend podcast, and in the wake of a colossal fall, we look at markets which ended the week on Friday the 13th, so far we’ve witnessed an emergency rate cut by the bank of England as the FTSE had its worst day in 33yrs. Alan Green shares some insight on the most recent events surrounding Corona…

Tiziana Life Sciences (Nasdaq: TSLA / AIM: TILS) Announces Pricing of U.S. Follow-On Offering of ADSs Raising $10 million March 12, 2020 – Posted in: Tiziana Life Sciences (TILS)

New York and London, March 12, 2020 – Tiziana Life Sciences plc (NASDAQ: TLSA; AIM: TILS) (the “Company” or “Tiziana”), a U.S. and U.K. biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology, today announced the pricing of its underwritten follow-on public offering (the “Offering”) of American Depositary Shares (“ADSs”) on the NASDAQ Global Market. Tiziana will issue 3,333,333 ADSs (representing 16,666,665 new ordinary shares…

Tiziana Life Sciences developing TZLS-501 as a potential treatment for Coronavirus patients March 11, 2020 – Posted in: Tiziana Life Sciences (TILS)

Nasdaq and AIM listed Tiziana Life Sciences plc (Nasdaq: TSLA / AIM: TILS) has today announced that its TZLS-501 treatment could be a potential treatment for patients infected with coronavirus (COVID-19) who are at risk of respiratory failure. Tiziana, a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, is expediting development of TZLS-501, with Novimmune, SA, a Swiss biotechnology company with whom it entered into a world-wide license for composition-of-matter in 2017.…

Tiziana Life Sciences (Nasdaq: TLSA; AIM: TILS) – TZLS-501 Potential Treatment of Certain Patients Infected with Coronavirus COVID-19 – Posted in: Tiziana Life Sciences (TILS)

New York/London, March 11, 2020 – Tiziana Life Sciences plc (Nasdaq: TLSA; AIM: TILS) (“Tiziana” or the “Company”), a biotechnology company focused on innovative therapeutics for inflammatory and autoimmune diseases, announced today that it is expediting development of TZLS-501, a novel, fully human anti-interleukin-6 receptor (anti-IL6R) monoclonal antibody (mAb) for treatment of patients infected with coronavirus COVID-19 (SARS-CoV-2). Tiziana plans to administer TZLS-501 using a proprietary formulation technology. The Company entered into a world-wide license for composition-of-matter…

Alan Green talks market crash, scaling in, Shell #RDSB, Open Orphan #ORPH & Eddie Stobart #ESL on Vox Markets podcast March 9, 2020 – Posted in: Blog, Open Orphan (ORPH)

Alan Green discusses the market crash, scaling in, Shell #RDSB, Open Orphan #ORPH & Eddie Stobart #ESL with Justin Waite on the Vox Markets podcast. Interview starts 9 minutes 49 seconds in.

Sunday Times – Coronavirus vaccine race: volunteers to be infected in the UK March 8, 2020 – Posted in: Open Orphan (ORPH)

Human guinea pigs in a London lab are to be given a form of the killer virus as the search for a lucrative jab hots up It sounds tempting: a payment of £3,500 to spend two weeks relaxing in front of the television, playing video games or catching up on some reading. There is a catch, however — you will be infected with a coronavirus and banned from physical contact with the outside world. As…

Open Orphan tip of the year update on mega contract win March 6, 2020 – Posted in: Open Orphan (ORPH)

by Tom Winnifrith Open Orphan (ORPH) was one of my tips of the year at a 4.6p offer. The shares are now 5.5p bid – the recent market sell off hitting it like nearly all other stocks. But the news today of a contract potentially worth £10 million plus really does slam home the message of how cheap the shares are. There are currently no broker forecasts out there but that is something that I…

Open Orphan #ORPH – New hVIVO contract signed with a European Biotech Company to provide RSV human challenge study – Posted in: Open Orphan (ORPH)

6 March 2020: Open Orphan plc (ORPH) the rapidly growing CRO specialist pharmaceutical services Group which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, is pleased to announce the signing of a new contract with a European Biotech Company for the provision of a RSV human challenge study. The study is projected to deliver £3.2m in revenue all of which is expected to be recognised in…

Alan Green discusses markets Eddie Stobart Logistics #ESL, Byotrol #BYOT, AstraZeneca #AZN & Metro Bank #MTRO on Vox Markets podcast March 2, 2020 – Posted in: Blog

Alan Green discusses markets Eddie Stobart #ESL, Byotrol #BYOT, AstraZeneca #AZN & Metro Bank #MTRO with Justin Waite on the Vox Markets podcast. Link on the image to listen.

Alan Green talks Coronavirus and markets, plus Open Orphan #ORPH & Metro Bank #MTRO on the UK Investor Magazine podcast February 27, 2020 – Posted in: Open Orphan (ORPH)

Alan Green discusses Coronavirus and markets, plus Open Orphan #ORPH & Metro Bank #MTRO with Jonathan Roy on the UK Investor Magazine podcast. Link on the image to listen.